Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 3.28Cr 2.32Cr 2.04Cr 1.92Cr 1.75Cr 222.49Cr 3.31Cr 23Cr 8.92Cr 113.67Cr 8.72Cr 8.53Cr 365.31Cr P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 3.26Cr 2.31Cr 2.02Cr 1.91Cr 1.74Cr 220.93Cr 3.28Cr 23Cr 8.85Cr 112.87Cr 8.65Cr 8.47Cr 362.74Cr EV / Sales 2024
-
EV / Sales 2025 2,42,35,81,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 01/07/2019
Director of Finance/CFO - 17/08/2022
Chief Tech/Sci/R&D Officer - 17/09/2024
Director TitleAgeSince
Director/Board Member - 06/12/2017
Director/Board Member - 01/07/2019
Chairman - 30/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+7.14% - - 2.32Cr
+0.13%+2.65%+65.61%+114.28% 1,05500Cr
+0.20%+0.46%+52.60%+69.24% 65TCr
-0.29%+0.14%+20.96%+70.93% 47TCr
-0.85%+0.98%+41.29%+44.38% 35TCr
+0.71%+4.08%+22.24%+29.51% 27TCr
+1.23%+0.42%+14.57%+12.13% 26TCr
+2.11%+7.51%+52.89%+55.37% 22TCr
+0.83%+0.55%+35.99%+101.70% 19TCr
0.00%-10.14%-29.94%-60.30% 17TCr
Average +0.32%+0.74%+30.69%+48.58% 40.43TCr
Weighted average by Cap. +0.02%+1.32%+41.54%+67.83%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.79 0.01 0.08 0.03 0.4 0.03 0.03 1.3
Net income -17.07L -12.08L -10.6L -10.01L -9L -12Cr -17.19L -1.2Cr -46.38L -5.91Cr -45.34L -44.36L -19Cr -35.33L -24.99L -21.93L -20.71L -18.87L -24Cr -35.58L -2.48Cr -95.98L -12Cr -93.81L -91.78L -39Cr
Net Debt -1L -79.67T -69.91T -66.02T -60.17T -76.36L -1L -8L -3L -39.01L -3L -3L -1.25Cr -2L -2L -1L -1L -1L -1.56Cr -2L -16.17L -6L -79.85L -6L -6L -2.57Cr
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-

Annual profits - Rate of surprise